Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

156
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

135
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
135
Human Genetics01:28

Human Genetics

2.0K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
2.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

1.6K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.6K
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

191
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
191

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The rs10781468 Genetic Polymorphism of the Gαq (GNAQ) Gene Is Associated With Responsiveness to Opioid Analgesics in Patients With Postoperative and Cancer Pain: An Exploratory Study.

Neuropsychopharmacology reports·2026
Same author

Sex Difference in Effect of the OPRM1 Gene A118G (rs1799971) Single-Nucleotide Polymorphism on the Requirement for Postoperative Fentanyl in Japanese Patients Who Underwent Laparoscopic-Assisted Colectomy.

Neuropsychopharmacology reports·2026
Same author

Genetic predispositions for anxiety disorders and major depressive disorder affect current dietary habits in older patients with lifestyle-related diseases.

The international journal of neuropsychopharmacology·2026
Same author

Runx1 transcription factor modulates opioid analgesia and withdrawal in humans and rodents.

Neuron·2026
Same author

Effect of the rs7858836 Single-Nucleotide Polymorphisms of the ASTN2 Gene on Pain-Related Phenotypes in Japanese Women Who Underwent Laparoscopic Gynecologic Surgery.

Neuropsychopharmacology reports·2025
Same author

Influences of genetic factors for educational attainment and cognitive functions on current dietary consumption.

iScience·2025

Related Experiment Video

Updated: Apr 26, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

1.8K

[Genetic polymorphisms commonly associated with sensitivity to various addictive substances].

Daisuke Nishizawa, Kazutaka Ikeda

    Nihon Shinkei Seishin Yakurigaku Zasshi = Japanese Journal of Psychopharmacology
    |July 30, 2014
    PubMed
    Summary

    Genetic variations in GIRK2 and GIRK3 genes are linked to how much pain medication patients need after surgery. One specific gene variation also correlates with addiction vulnerability, offering insights into personalized pain and addiction treatment.

    More Related Videos

    Flypub To Study Ethanol Induced Behavioral Disinhibition and Sensitization
    08:13

    Flypub To Study Ethanol Induced Behavioral Disinhibition and Sensitization

    Published on: May 18, 2020

    8.0K
    An Inexpensive, Scalable Behavioral Assay for Measuring Ethanol Sedation Sensitivity and Rapid Tolerance in Drosophila
    07:28

    An Inexpensive, Scalable Behavioral Assay for Measuring Ethanol Sedation Sensitivity and Rapid Tolerance in Drosophila

    Published on: April 15, 2015

    9.9K

    Related Experiment Videos

    Last Updated: Apr 26, 2026

    Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
    09:29

    Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

    Published on: August 4, 2022

    1.8K
    Flypub To Study Ethanol Induced Behavioral Disinhibition and Sensitization
    08:13

    Flypub To Study Ethanol Induced Behavioral Disinhibition and Sensitization

    Published on: May 18, 2020

    8.0K
    An Inexpensive, Scalable Behavioral Assay for Measuring Ethanol Sedation Sensitivity and Rapid Tolerance in Drosophila
    07:28

    An Inexpensive, Scalable Behavioral Assay for Measuring Ethanol Sedation Sensitivity and Rapid Tolerance in Drosophila

    Published on: April 15, 2015

    9.9K

    Area of Science:

    • Genetics and Molecular Biology
    • Neuroscience
    • Pharmacology

    Context:

    • Opioids are crucial for pain management but also play a role in drug reward pathways.
    • G-protein-activated inwardly rectifying potassium (GIRK) channel subunits (GIRK2 and GIRK3) are key in opioid signaling.
    • Genetic variations, specifically single-nucleotide polymorphisms (SNPs), can influence individual responses to opioids and addictive substances.

    Purpose:

    • To investigate the association between SNPs in the GIRK2 and GIRK3 gene regions and postoperative analgesic requirements.
    • To identify specific SNPs, like rs2952768, linked to opioid analgesic needs and vulnerability to drug dependence.
    • To explore the relationship between genetic factors, pain management, and addiction susceptibility.

    Summary:

    • A genome-wide association study identified the rs2952768 SNP strongly associated with the need for postoperative opioid analgesics in cosmetic and abdominal surgery patients.
    • This SNP was also linked to increased vulnerability to severe drug dependence (methamphetamine, alcohol) and eating disorders.
    • Furthermore, rs2952768 correlated with lower 'Reward Dependence' scores in healthy individuals, suggesting a role in personality traits related to addiction.

    Impact:

    • Provides valuable genetic markers for predicting individual responses to opioid analgesics.
    • Offers potential targets for personalized pain management strategies, optimizing dosage and reducing risks.
    • Contributes to a deeper understanding of the genetic underpinnings of addiction vulnerability and reward processing.
    • Informs the development of tailored treatments for both pain and substance use disorders.